Login to Your Account

Opthea aims to improve VEGF-A with AMD combo therapy; raises $33M

By Tamra Sami
Staff Writer

Tuesday, April 11, 2017

PERTH, Australia – Melbourne-based Opthea Ltd.'s recent A$45 million equity financing will go toward expanding clinical development of its VEGF-C/D trap therapy candidate, OPT-302, for wet AMD and DME.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription